CN104367566A - Indomethacin cataplasm and composition thereof - Google Patents
Indomethacin cataplasm and composition thereof Download PDFInfo
- Publication number
- CN104367566A CN104367566A CN201310350111.0A CN201310350111A CN104367566A CN 104367566 A CN104367566 A CN 104367566A CN 201310350111 A CN201310350111 A CN 201310350111A CN 104367566 A CN104367566 A CN 104367566A
- Authority
- CN
- China
- Prior art keywords
- indomethacin
- crotamiton
- methyl pyrrolidone
- weight
- cataplasm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides an indomethacin cataplasm, which is composed of a backing, a paste body, and an anti-sticking film, wherein the paste body is composed of indomethacin, crotamiton, N-methyl pyrrolidone, and hydrogel matrix; the content of the indomethacin in the paste body is 0.1 to 3 wt%, the weight of crotamiton is 0.1 to 6 times as heavy as that of indomethacin, the weight of N-methyl pyrrolidone is 1 to 15 times as heavy as that of indomethacin, and the balance being hydrogel matrix. The mixed solvent of crotamiton and N-methyl pyrrolidone can increase the solubility of indomethacin so as to completely dissolve indomethacin, the indomethacin is evenly dispersed in hydrogel matrix and will not crystallize for a long time, moreover the skin penetrating performance of indomethacin is improved, and indomethacin can be more easily absorbed by the skin. Furthermore, a skin penetration promoter and a wetting agent are added to ensure that the cataplasm has a high water content and remains wet for a long time, and the skin penetration and absorption of the drugs are also promoted. The provided indomethacin cataplasm can be used to treat arthralgia diseases such as rheumatic arthritis, gouty arthritis, rigidity myelitis, tenosynovitis, and the like.
Description
Technical field
The present invention relates to a kind of hydrophilic cataplasma, particularly relate to that a kind of water content is high, stability and the good indomethacin cataplasm of transdermal characteristic and Indomethacin Compositions.
Background technology
Indomethacin (Indomethacin) is one of typical medicaments of non-steroidal anti-inflammatory analgesics, mainly produces analgesia, antiinflammatory and refrigeration function by suppressing prostaglandin (PG) synthesis in body.Be usually used in the treatment of acute and chronic rheumatic arthritis, gouty arthritis, tatanic myelitis and the disease such as bursitis, tenosynovitis and osteoarthritis, cervical spondylosis, myalgia, pain in the lumbar region clinically.
Clinical discovery Long-term Oral indomethacin, has seriously side effect to gastrointestinal tract, as the mucosa that stimulates digestion, and then causes gastrorrhagia or gastric ulcer; In addition, also side reaction is had to central nervous system, as dizzy, the insomnia of having a headache, ataxia etc.Absorb to reduce indomethacin oral administration the side effect produced, modern medicinal agents worker have studied external preparation, as cataplasma, emulsifiable paste, liniment etc.Wherein, emulsifiable paste and liniment short for action time, administration number of times is frequent; Dosage inaccuracy, causes drug effect unstable; Easily there are the shortcomings such as mastic residual contamination medicated clothing.
Cataplasma is a kind of Novel external patch, and compared with conventional rubber cream, it is large that cataplasma has drug loading, and moisture retention is strong, has the good compatibility, convenient drug administration with skin, and dosage is accurate, can produce the advantages such as lasting therapeutical effect.Cataplasma take hydrophilic high molecular material as substrate, and rate of releasing drug is fast, and release meets zero order release rate equation, makes blood drug level in patient body constant, reduces the generation of untoward reaction; In addition, cataplasma moisturizing, ventilative, repeatedly can take off subsides, the non-stimulated and anaphylaxis to skin.
At present, the topmost problem that cataplasma exists how to overcome skin barrier.The lipophilic horny layer of skin and hydrophilic viable skin layer (epidermis and corium) together constitute the barrier of percutaneous drug absorption.Therefore, medicine needs suitable fat-soluble and water solublity, could absorb through biomembrane lipid bilayer.Indomethacin is insoluble drug, and its poor solubility in water, oil have impact on the Transdermal absorption of medicine.Therefore, improving the dissolubility of indomethacin, improve stability, and ensure to store stability, is be made into the matter of utmost importance being easy to transdermal absorption formulation and solving.Carry out much research at present and made great efforts to solve these problems, but not found one method safely and effectively yet.
Such as, CN102526001A utilizes ion pair technology by indomethacin and organic amine salify, increases its dissolubility, but the salt of these class methods synthesis easily decomposes by the impact of the condition such as temperature, pH, poor stability; Also have and adopt solubilizing agent and transdermal penetration enhancer, as alkyl pyrrolidone, azone+propylene glycol (CN1973836A), but indomethacin dissolubility in aqueous matrix is low, and long-time storage may occur crystallization, cause the Transdermal absorption performance of this medicine poor.
Summary of the invention
The object of the invention is to overcome above-mentioned deficiency, Transdermal absorption, water content are high, persistent and bland indomethacin Hydrophillia Babu agent to provide one to be easy to.Furthermore, the object of the invention is research indomethacin aqueous cataplasma, make it in preparation and storage, have good steady dissolution, demonstrate high-moisture and long moisture retention, to ensure the sustained release of medicine and to improve the Transdermal absorption performance of medicine.
First aspect of the present invention is to provide a kind of indomethacin cataplasm, comprises backing (conventional non-woven fabrics or stretch fabric etc.), mastic and anti-mucosa, wherein:
In mastic, the content of indomethacin is preferably 0.1-3wt%, is more preferably 0.2-2wt%, is more preferably 0.2-1.5wt%, is more preferably 0.3-1wt%;
In mastic, the weight of crotamiton is preferably the 0.1-6 of indomethacin doubly, is more preferably 0.2-4 doubly, is more preferably 0.5-3 doubly, is more preferably 1-2.5 doubly, is more preferably 1.5-2 doubly;
In mastic, the weight of N-Methyl pyrrolidone is preferably the 1-15 of indomethacin doubly, is more preferably 1.5-10 doubly, is more preferably 1.5-9 doubly, is more preferably 2-8 doubly, is more preferably 3.5-6 doubly, is more preferably 4-5.2 doubly.
In a kind of preferred embodiment in the present invention first, described cataplasma is made up of backing (conventional non-woven fabrics or stretch fabric etc.), mastic and anti-mucosa, described mastic constituent comprises indomethacin, solvent and aqueous gel substrate, hydrophilic transdermal absorbable preparation is prepared into through cataplasma moulding process, wherein, described solvent comprises crotamiton and N-Methyl pyrrolidone; Wherein:
In mastic, the content of indomethacin is preferably 0.1-3wt%, is more preferably 0.2-2wt%, is more preferably 0.2-1.5wt%, is more preferably 0.3-1wt%;
In mastic, the weight of crotamiton is preferably the 0.1-6 of indomethacin doubly, is more preferably 0.2-4 doubly, is more preferably 0.5-3 doubly, is more preferably 1-2.5 doubly, is more preferably 1.5-2 doubly;
In mastic, the weight of N-Methyl pyrrolidone is preferably the 1-15 of indomethacin doubly, is more preferably 1.5-10 doubly, is more preferably 1.5-9 doubly, is more preferably 2-8 doubly, is more preferably 3.5-6 doubly, is more preferably 4-5.2 doubly; Surplus is aqueous gel substrate.
Preferably, the constituent of the above-mentioned any aqueous gel substrate of the present invention comprises and preferably consists of: hydrophilic basis material 0.1-40wt%, more preferably 0.5-30wt%, more preferably 5-25wt%, more preferably 10-20wt%;
Cross-linking agent 0.01-2wt%, more preferably 0.02-1wt%, more preferably 0.05-0.8wt%, more preferably 0.1-0.6wt%, more preferably 0.3-0.5wt%;
Cross-linking regulator 0.01-4wt%, more preferably 0.02-2wt%, more preferably 0.08-1.5wt%, more preferably 0.12-1wt%, more preferably 0.3-0.7wt%;
Wetting agent 10-60wt%, more preferably 19-50wt%, more preferably 20-50wt%, more preferably 25-42wt%, more preferably 30-38wt%;
Transdermal penetration enhancer 0.05-45wt%, more preferably 0.1-30wt%, more preferably 2-25wt%, more preferably 5-20wt%, more preferably 10-16wt%;
Water 10-85wt%, more preferably 20-80wt%, more preferably 30-68wt%, more preferably 38-56wt%, more preferably 45-50wt%.
But described hydrophilic basis material hydrophilic high molecular material, wherein, hydrophilic high molecular material can be selected from 1) cellulose and its derivates, as carboxymethyl cellulose, carboxymethyl cellulose salt, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose, hydroxyethyl-cellulose etc.; 2) synthesized polymer material, as polyvinyl alcohol, carbomer, polyacrylic acid, polyacrylate or ester, poly acrylic acid-poly sodium acrylate copolymer (as NP-700), poly acrylic acid-poly sodium acrylate copolymer (as NP-600), poly acrylic acid-poly sodium acrylate copolymer (as NP-800), polyvinylpyrrolidone (PVP), polybutene, carboxylic polrvinyl; 3) other comes from the hydrophilic colloid of organism, polysaccharide, polypeptide or its hydrophilic derivatives, and as gelatin, arabic gum, alginate, alginic acid, alginate, chitosan etc., described hydrophilic high molecular material can be one or more in above-mentioned substance; Described salt can be potassium salt, sodium salt, calcium salt etc.
Cross-linking agent used can be selected from aluminium hydroxide, calcium hydroxide, dihydroxyaluminum aminoacetate, aluminum chloride, aluminium oxide, calcium chloride, aluminium citrate, synthetic aluminium silicate, dihydroxyaluminum aminoacetate, glutamic acid aluminum etc. in interior one or more.
Cross-linking regulator used can be selected from tartaric acid, citric acid, malic acid, edetic acid (EDTA), gluconic acid or its salt etc. in interior one or more, and described salt can be potassium salt, sodium salt, calcium salt etc., as EDETATE DISODIUM.
Wetting agent used is preferably polyhydric alcohol, can be selected from ethylene glycol, Polyethylene Glycol (as PEG-400, PEG-600, PEG-800), glycerol, propylene glycol, polypropylene glycol, D-glucitol, 1,3 butylene glycol, hexanediol, xylitol, liquid paraffin etc. in interior one or more.
Transdermal penetration enhancer used can be selected from laurocapram, Oleum menthae, eucalyptus oil, carbamide, dimethyl sulfoxide, propylene glycol, polyvinyl alcohol, soft phospholipid, phosphatidyl glycerol, TC, N-Methyl pyrrolidone (NMP), SA diethylester, oleic acid, oleyl alcohol, diisopropyl adipate, octyldodecanol, benzylalcohol, isopropyl myristate, lauryl alcohol, 2-octyldodecanol, ethyl 2 ethyl hexanoic acid, calcium mercaptoacetate, the last of the ten Heavenly stems monoglyceride, caprylate, the last of the ten Heavenly stems ester, decyl oleate, squalane and/or D-limonene etc. are in interior one or more.
Surfactant used can be ion-type or nonionic surfactant, and be preferably anionic surfactant, any one or a few in nonionic surfactant, can be selected from Polysorbate (as tween 80), sodium lauryl sulphate, dioctyl succinate disulfonate acid, Span, glyceryl monostearate, polyoxyethylene hydrogenated Oleum Ricini etc. in interior one or more.
In addition, described mastic can also comprise one or more in antiseptic, adhesive agent, filler, antioxidant, freshener.Wherein:
Described antiseptic can be selected from parabens (as methyl hydroxybenzoate, ethyl hydroxybenzoate etc.), benzoic acid, ethylparaben, benzalkonium chloride etc. in interior one or more.
Adhesive agent can be selected from polyvinylpyrrolidone (as PVPK30), polyacrylic acid etc. at interior one or both.
Filler can be selected from micropowder silica gel, calcium carbonate, Kaolin, Bentonite, zinc oxide, titanium dioxide etc. in interior one or more.
Antioxidant can be selected from sodium sulfite, sodium pyrosulfite, citric acid, dibenzylatiooluene, Butylated hydroxyanisole, ethylenediaminetetraacetic acid etc. in interior one or more.
Freshener can be selected from Mentholum, Camphora, menthol, Herba Menthae wet goods in interior one or more.
Second aspect of the present invention is to provide a kind of Indomethacin Compositions, comprise indomethacin, crotamiton and N-Methyl pyrrolidone, the weight of crotamiton is 0.1-6 times of indomethacin, be more preferably 0.2-4 doubly, be more preferably 0.5-3 doubly, be more preferably 1-2.5 doubly, be more preferably 1.5-2 doubly; The weight of N-Methyl pyrrolidone is 1-15 times of indomethacin, is more preferably 1.5-10 doubly, is more preferably 1.5-9 doubly, is more preferably 2-8 doubly, is more preferably 3.5-6 doubly, is more preferably 4-5.2 times.
Preferably, described Indomethacin Compositions also comprises aqueous gel substrate, wherein, in Indomethacin Compositions, the content of indomethacin is more preferably 0.2-2wt% for being preferably 0.1-3wt%(, be more preferably 0.2-1.5wt%, be more preferably 0.3-1wt%), aqueous gel substrate surplus.
Preferably, the constituent of described aqueous gel substrate comprises:
Hydrophilic basis material 0.1-40wt%, more preferably 0.5-30wt%, more preferably 5-25wt%, more preferably 10-20wt%;
Cross-linking agent 0.01-2wt%, more preferably 0.02-1wt%, more preferably 0.05-0.8wt%, more preferably 0.1-0.6wt%, more preferably 0.3-0.5wt%;
Cross-linking regulator 0.01-4wt%, more preferably 0.02-2wt%, more preferably 0.08-1.5wt%, more preferably 0.12-1wt%, more preferably 0.3-0.7wt%;
Wetting agent 10-60wt%, more preferably 19-50wt%, more preferably 20-50wt%, more preferably 25-42wt%, more preferably 30-38wt%;
Transdermal penetration enhancer 0.05-45wt%, more preferably 0.1-30wt%, more preferably 2-25wt%, more preferably 5-20wt%, more preferably 10-16wt%;
Water 10-85wt%, more preferably 20-80wt%, more preferably 30-68wt%, more preferably 38-56wt%, more preferably 45-50wt%.
Described Indomethacin Compositions can also comprise one or more in antiseptic, adhesive agent, filler, antioxidant, freshener.
Hydrophilic basis material, cross-linking agent, cross-linking regulator, wetting agent, transdermal penetration enhancer, antiseptic, adhesive agent, filler, antioxidant, freshener etc. described in the present invention second aspect, have identical implication and weight proportion scope respectively with hydrophilic basis material, cross-linking agent, cross-linking regulator, wetting agent, transdermal penetration enhancer, antiseptic, adhesive agent, filler, antioxidant, freshener etc. described in the present invention first aspect respectively.
Applicant finds: crotamiton and N-Methyl pyrrolidone used in combination time can increase the dissolubility of indomethacin, but when crotamiton consumption is excessive, long-time placement understands variable color, less stable, and consumption is too small, and indomethacin is poorly soluble; N-Methyl pyrrolidone consumption is excessive, poor stability and easily produce stink, and the very few indomethacin of consumption is poorly soluble, and percutaneous abilities is also just deteriorated.Applicant is 0.1-6 times, preferably 0.2-4 times of indomethacin at the consumption of crotamiton through great many of experiments discovery, the consumption of N-Methyl pyrrolidone be the 1-15 of indomethacin doubly, preferably 1.5-10 times time, indomethacin dissolves completely, and good stability, and be dispersed in the medium-term and long-term not easily crystallization of aqueous gel substrate.
Indomethacin cataplasm provided by the invention take indomethacin as active component, the mixed solvent of crotamiton and N-Methyl pyrrolidone is adopted to increase the dissolubility of indomethacin, indomethacin is made to dissolve completely, and be dispersed in the medium-term and long-term not easily crystallization of aqueous gel substrate, increase the Transdermal absorption performance of indomethacin; The transdermal penetration enhancer added, wetting agent etc. ensure that indomethacin cataplasm high-moisture and long time moisture retention, increase the Transdermal absorption of medicine.The U.S. pungent cataplasma of diindyl provided by the invention can be used for the various arthralgia diseases such as rheumatic arthritis, gouty arthritis, tatanic myelitis, tenosynovitis, myalgia, pain in the lumbar region.
Detailed description of the invention
Referring to specific embodiment, the invention will be further described, to understand the present invention better.
Embodiment 1
The indomethacin cataplasm that the present embodiment provides is made up of backing, mastic and anti-mucosa, and the constituent of described mastic comprises:
First 2.0g sodium carboxymethyl cellulose is dissolved in glycerol and partial purification water, then adds 1.0g Vinlub 73 and 0.1g Tween 80, be heated to 40 DEG C, stir, obtain component A;
Get 1g Gelatin in partial purification water, expand complete post-heating to 60 DEG C, stirs to translucent colloid, obtained B component;
5.0g sodium polyacrylate part corrective, 0.06g aluminium hydroxide and 0.15g disodium edetate are dissolved in glycerol, are uniformly mixed, obtained component C;
Join in purified water by 0.12g tartaric acid, then add the indomethacin solution be dissolved in advance in crotamiton, N-Methyl pyrrolidone, mixing, stirs, obtains D component;
Get residue purified water in prefabricated tanks, add component A, B component, component C, make its fully refine and, be uniformly dispersed, then add D component, about 40-50 DEG C of insulation, mix, stir, make cream.By cream even spread, section, packaging, obtained cataplasma.
Embodiment 2
The indomethacin cataplasm that the present embodiment provides is made up of backing, mastic and anti-mucosa, and the constituent of described mastic comprises:
First 2.0g sodium carboxymethyl cellulose is dissolved in glycerol and partial purification water, then adds 1.0g Vinlub 73 and 0.1g Tween 80, be heated to 40 DEG C, stir, obtain component A;
Get 2.0g Gelatin in partial purification water, expand complete post-heating to 60 DEG C, stirs to translucent colloid, obtained B component;
6.0g sodium polyacrylate part corrective, 0.05g aluminium hydroxide and 0.15g disodium edetate are dissolved in glycerol, are uniformly mixed, obtained component C;
Join in purified water by 0.12g tartaric acid, then add the indomethacin solution be dissolved in advance in crotamiton, N-Methyl pyrrolidone, mixing, stirs, obtains D component;
Get residue purified water in prefabricated tanks, add methyl hydroxybenzoate, then add component A, B component, component C, make its fully refine and, be uniformly dispersed, then add D component, about 40-50 DEG C of insulation, mix, stir, make cream.By cream even spread, section, packaging, obtained cataplasma.
Embodiment 3
The indomethacin cataplasm that the present embodiment provides is made up of backing, mastic and anti-mucosa, and the constituent of described mastic comprises:
First 2.0g sodium carboxymethyl cellulose is dissolved in glycerol and partial purification water, then adds 1.0g carboxylic polrvinyl, 0.3g polyoxyethylene hydrogenated Oleum Ricini and 0.1g Tween 80, be heated to 40 DEG C, stir, obtain component A.
Get 1.0g Gelatin in partial purification water, expand complete post-heating to 60 DEG C, stirs to translucent colloid, obtained B component;
6.0g sodium polyacrylate part corrective, 0.05g aluminium hydroxide and 0.15g disodium edetate are dissolved in glycerol, are uniformly mixed, obtained component C;
Join in purified water by 0.12g tartaric acid, then add the indomethacin solution be dissolved in advance in crotamiton, N-Methyl pyrrolidone, mixing, stirs, obtains D component;
Get residue purified water in prefabricated tanks, add component A, B component, component C, make its fully refine and, be uniformly dispersed, then add D component, about 40-50 DEG C of insulation, mix, stir, make mastic.By mastic even spread, section, packaging, obtained cataplasma.
1, stability test
Prepare cataplasma according to embodiment 1 and example 3, by cataplasma respectively with aluminium plastic packaging bag sealing, be placed on 40 DEG C, preserve in 75% calorstat, measure indomethacin content in the 0-6 month, result is as shown in table 1, and in June, indomethacin content is basicly stable.(temperature 30 DEG C, relative humidity are 60%) places 24 months at ambient temperature, respectively at sampling in 0,1,2,3,24 month, measure indomethacin content, result is as shown in table 2, indomethacin stable content in 24 months, do not occur that crystal is separated out, illustrate that indomethacin of the present invention has good stability.
Indomethacin relative amount under table 1 high temperature (40 DEG C)
| Sample time | 0 | January | March | June |
| Embodiment 1 | 100.00% | 98.12% | 94.26% | 93.58% |
| Embodiment 3 | 100.00% | 97.70% | 95.14% | 93.83% |
Indomethacin relative amount under table 2 room temperature (30 DEG C, relative humidity 60%)
| Sample time | 0 | 1 month | 2 months | 3 months | 24 months |
| Embodiment 1 | 100.00% | 98.14% | 98.64% | 98.13% | 96.56% |
| Embodiment 3 | 100.00% | 99.27% | 99.85% | 98.74% | 97.98% |
2, Ligustrazine hydrochloride test
Adopt improved Franz diffusing cells method, be fixed on by mouse skin on diffusion cell, corium is towards receiving chamber, and stratum corneum side, to supply chamber, adds appropriate phosphate buffered solution in receiving chamber.Cataplasma obtained for embodiment 1 is affixed on skin, opens constant temperature (32 ± 1) DEG C water-bath circulation and magnetic stirring apparatus (300rmin
-1) different time points 2,4,6,8,12,24h sampling, utilize high phase liquid chromatography for measuring indomethacin content, Q is unit area Percutaneous permeability, the results are shown in Table 3.
Table 3 Ligustrazine hydrochloride result of the test
| Transdermal time (h) | 2 | 4 | 6 | 8 | 12 | 24 |
| Q(μg·cm -2) | 19.30 | 40.98 | 54.62 | 72.54 | 136.13 | 230.69 |
As shown in Table 3, the percutaneous rate of the indomethacin cataplasm that the embodiment of the present invention 1 is obtained is 9.79 μ gcm
-2h
-1, illustrate that indomethacin cataplasm percutaneous abilities provided by the invention is good.
3, irritation test
Get 24 SD rats, male and female half and half, body weight is about 160-180g, is equally divided into three groups, and skin of abdomen is shaved removed with being shaved a mao machine.First group of rat applies ointment or plaster in epilating area (2 × 3) cm
2the obtained indomethacin cataplasm of embodiment 1, divest after 24, second group of blank cataplasma of tester of applying ointment or plaster in epilating area, divests after 24, after divesting after 3rd group of successive administration 14d, observe when divesting, divesting 24h, divest 48h after, 7 divest 2h after to lose hair or feathers district's irriate situation.All there is not the anaphylaxis such as erythema and edema in the skin that result shows the depilation district of three groups of rats, illustrate that this cataplasma is to no skin irritation, safety is good.
In sum, indomethacin Hydrophillia Babu agent provided by the invention has good stability, water content is high, moisture retention is strong, Transdermal absorption performance good, to no skin irritation.
Be described in detail specific embodiments of the invention above, but it is just as example, the present invention is not restricted to specific embodiment described above.To those skilled in the art, any equivalent modifications that the present invention is carried out and substituting also all among category of the present invention.Therefore, equalization conversion done without departing from the spirit and scope of the invention and amendment, all should contain within the scope of the invention.
Claims (10)
1. an indomethacin cataplasm, comprises backing, mastic and anti-mucosa, it is characterized in that, described mastic constituent comprises indomethacin, solvent and aqueous gel substrate, is prepared into hydrophilic transdermal absorbable preparation through cataplasma moulding process; Wherein, in mastic, the content of indomethacin is 0.1-3wt%, and described solvent comprises crotamiton and N-Methyl pyrrolidone, and the weight of crotamiton is 0.1-6 times of indomethacin, and the weight of N-Methyl pyrrolidone is 1-15 times of indomethacin.
2. indomethacin cataplasm according to claim 1, by it is characterized in that, the weight of crotamiton is 0.2-4 times of indomethacin, and the weight of N-Methyl pyrrolidone is 1.5-10 times of indomethacin.
3. indomethacin cataplasm according to claim 2, by it is characterized in that, the constituent of described aqueous gel substrate comprises:
4. indomethacin cataplasm according to claim 1, by it is characterized in that, the constituent of described aqueous gel substrate comprises:
5. indomethacin cataplasm according to claim 3, by it is characterized in that, described hydrophilic basis material selected from cellulose and derivant thereof, hydrophilic synthesized polymer material, other come from the hydrophilic colloid of organism, polysaccharide, polypeptide or its hydrophilic derivatives, hydrophilic clay one or more.
6. indomethacin cataplasm according to claim 3, by it is characterized in that, described transdermal penetration enhancer is laurocapram, Oleum menthae, eucalyptus oil, carbamide, dimethyl sulfoxide, propylene glycol, polyvinyl alcohol, soft phospholipid, phosphatidyl glycerol, TC, N-Methyl pyrrolidone, SA diethylester, oleic acid, oleyl alcohol, diisopropyl adipate, octyldodecanol, benzylalcohol, isopropyl myristate, lauryl alcohol, 2-octyldodecanol, ethyl 2 ethyl hexanoic acid, calcium mercaptoacetate, the last of the ten Heavenly stems monoglyceride, caprylate, the last of the ten Heavenly stems ester, decyl oleate, one or more in squalane and/or D-limonene.
7. an Indomethacin Compositions, is characterized in that, comprises indomethacin, crotamiton and N-Methyl pyrrolidone, and the weight of crotamiton is 0.1-6 times of indomethacin, and the weight of N-Methyl pyrrolidone is 1-15 times of indomethacin.
8. Indomethacin Compositions according to claim 7, is characterized in that, the weight of crotamiton is 0.2-4 times of indomethacin, and the weight of N-Methyl pyrrolidone is 1.5-10 times of indomethacin.
9. the Indomethacin Compositions according to claim 7 or 8, is characterized in that, also comprises aqueous gel substrate, and wherein, in Indomethacin Compositions, the content of indomethacin is 0.1-3wt%, aqueous gel substrate surplus.
10. Indomethacin Compositions according to claim 9, is characterized in that, the constituent of described aqueous gel substrate comprises:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310350111.0A CN104367566A (en) | 2013-08-12 | 2013-08-12 | Indomethacin cataplasm and composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310350111.0A CN104367566A (en) | 2013-08-12 | 2013-08-12 | Indomethacin cataplasm and composition thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104367566A true CN104367566A (en) | 2015-02-25 |
Family
ID=52546931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310350111.0A Pending CN104367566A (en) | 2013-08-12 | 2013-08-12 | Indomethacin cataplasm and composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104367566A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287361A (en) * | 2015-11-13 | 2016-02-03 | 北京泰德制药股份有限公司 | External preparation containing non-steroid anti-inflammatory drug microemulsion and used for skin |
| CN107198681A (en) * | 2017-05-16 | 2017-09-26 | 蔡志浩 | A kind of Indomethacin hydrogel patch |
| CN111297893A (en) * | 2019-12-18 | 2020-06-19 | 杭州仁德医药有限公司 | Compound indomethacin and dyclonine plaster with waterproof performance and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1973836A (en) * | 2006-12-01 | 2007-06-06 | 中国人民解放军第二军医大学 | Hydrophilic plaster for treating dysmenorrhea |
| CN102065896A (en) * | 2008-06-16 | 2011-05-18 | 帝国制药株式会社 | Analgesic anti-inflammatory preparation for external application |
-
2013
- 2013-08-12 CN CN201310350111.0A patent/CN104367566A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1973836A (en) * | 2006-12-01 | 2007-06-06 | 中国人民解放军第二军医大学 | Hydrophilic plaster for treating dysmenorrhea |
| CN102065896A (en) * | 2008-06-16 | 2011-05-18 | 帝国制药株式会社 | Analgesic anti-inflammatory preparation for external application |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287361A (en) * | 2015-11-13 | 2016-02-03 | 北京泰德制药股份有限公司 | External preparation containing non-steroid anti-inflammatory drug microemulsion and used for skin |
| CN107198681A (en) * | 2017-05-16 | 2017-09-26 | 蔡志浩 | A kind of Indomethacin hydrogel patch |
| CN111297893A (en) * | 2019-12-18 | 2020-06-19 | 杭州仁德医药有限公司 | Compound indomethacin and dyclonine plaster with waterproof performance and preparation method thereof |
| CN111297893B (en) * | 2019-12-18 | 2021-11-12 | 杭州仁德医药有限公司 | Compound indomethacin and dyclonine plaster with waterproof performance and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10238612B2 (en) | Transdermal administration of tamsulosin | |
| US6239177B1 (en) | Tranilast-containing preparation for external application and method of producing the same | |
| JP5020061B2 (en) | Transdermal preparation | |
| CN104546803A (en) | Flurbiprofen hydrogel plaster and composition thereof | |
| JPH06305958A (en) | Plaster antiphlogistic analgesic plaster for external use | |
| EP2491924B1 (en) | Water-based paste containing diclofenac sodium | |
| EP2777692B1 (en) | Composition for enhancing transdermal absorption of drug and patch preparation | |
| ES2504065T3 (en) | Stable Rasagiline Composition | |
| CN102379862B (en) | Spirosal-containing hydrophilic cataplasm | |
| CN113041236B (en) | Flurbiprofen cataplasm and preparation method thereof | |
| CN104367566A (en) | Indomethacin cataplasm and composition thereof | |
| WO2009125667A1 (en) | Water-based adhesive skin patch containing butenafine hydrochloride | |
| KR100322988B1 (en) | Anti-inflammatory analgesic compositions and anti-inflammatory analgesics containing them | |
| US20050158371A1 (en) | Novel external agent | |
| KR100552650B1 (en) | Antiphlogistic and analgesic plaster comprising Piroxicam compound | |
| JP4795514B2 (en) | Patch | |
| CN104415024A (en) | Diclofenac-containing cataplasm, and composition and preparation method thereof | |
| JP2002029971A (en) | Indomethacin water-soluble cataplasm | |
| KR20050077426A (en) | Plaster comprising non-steroidal anti-inflammatory drugs | |
| JP4410431B2 (en) | Felbinac-containing patch | |
| KR20070071534A (en) | Transdermal delivery system of non-steroidal anti-inflammatory drugs | |
| KR20190048320A (en) | Varenicline percutaneous drug delivery system | |
| WO2001013938A1 (en) | Medicinal composition for percutaneous/permucosal absorption | |
| KR20080067753A (en) | The composition of plaster containing felbinacs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150225 |
|
| RJ01 | Rejection of invention patent application after publication |